Finland· FI-REL-REL63367
Kyinsu
A insulin icodec und semaglutid product containing insulin icodec + semaglutide, registered in Finland by Novo Nordisk A/S. The same ATC class is registered in 6 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Insulin icodec und semaglutid is registered in 6 of 19 countries.
Countries holding a registration under ATC A10AE57 (insulin icodec und semaglutid), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 4 of them publish a price we can compare per daily dose
Insulin icodec und semaglutid · ATC A10AE57
6 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
The record
At a glance
Fimea (Finland)- Active substance
- Insulin icodec + Semaglutide
- Manufacturer
- Novo Nordisk A/S
- Country
- Finland (FI)
- ATC code
- A10AE57
- ATC class
- Insulin Icodec und Semaglutid
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin icodec und semaglutid in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKYINSUNovo Nordisk A/S, Bagsvaerd
- IrelandKyinsu (700 units + 2 mg)/mL solution for injection in pre-filled penNovo Nordisk A/S
- IcelandKyinsuNovo Nordisk A/S
- NetherlandsKyinsu (700 eenheden + 2 mg)/ml oplossing voor injectie in een voorgevulde penNovo Nordisk A.S.
- PolandKyinsuNovo Nordisk A/S
- SwedenKyinsu 700 IE/ml + 2 mg/ml Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Kyinsu
- Norway · Kyinsu
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a1acece6-cb0c-4d59-9b09-e79b2620f0e9 GET /v1/drugs/a1acece6-cb0c-4d59-9b09-e79b2620f0e9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektioneste, liuos, esitäytetty kynä",
"route": "Ihon alle",
"ddd_unit": null,
"strength": "700 U/ml + 2 mg/ml",
"atc_label": "ikodekinsuliini ja semaglutidi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/25/1992/001-006",
"fimea_rel_id": "REL63367",
"authorised_at": "2025-11-24"
}See everything about insulin icodec und semaglutid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.